Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases

Dima A. Sabbah, Neka A. Simms, Michael G. Brattain, Jonathan L. Vennerstrom, Haizhen Zhong

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


The alpha isoform of the phosphatidylinositol-3-kinases (PI3Kα) is often mutated, amplified and overexpressed in human tumors. In an effort to develop new inhibitors targeting this enzyme, we carried out a pharmacophore model study based on six PI3Kα-selective compounds. The pharmacophore searching identified three structurally novel inhibitors of PI3Kα and its H1047R mutant. Our biological studies show that two of our hit molecules suppressed the formation of pAKT, a downstream effector of PI3Kα, and induced apoptosis in the HCT116 colon cancer cell line. QPLD-based docking showed that residues Asp933, Glu849, Val851, and Gln859 appeared to be key binding residues for active inhibitors.

Original languageEnglish (US)
Pages (from-to)876-880
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Issue number2
StatePublished - Jan 15 2012


  • Apoptosis
  • Docking
  • GSK2126458
  • LY294002
  • PI3K
  • Pharmacophore modeling

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry


Dive into the research topics of 'Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases'. Together they form a unique fingerprint.

Cite this